RaeSedo, Inc. is focused on developing innovative asthma therapeutics that target the underlying inflammation associated with the disease. The company has identified surfactant protein-A (SP-A) as a key player in the respiratory system's defense against environmental irritants and infections. Their research has revealed that some asthma patients exhibit dysfunctional SP-A or low levels of this protein, particularly in those with obesity. RaeSedo is working on creating small peptide therapeutics derived from SP-A that can mimic its anti-inflammatory effects. These peptidomimetics aim to reduce eosinophil accumulation, inhibit mucus production, and alleviate airway hyperresponsiveness, thereby addressing the severe symptoms experienced by asthma patients.

The company’s approach is grounded in extensive preclinical studies that demonstrate the efficacy of SP-A-derived peptides in reducing inflammation and promoting lung health. RaeSedo's research highlights the correlation between eosinophil viability and asthma severity, suggesting that targeting these immune cells could lead to better management of asthma exacerbations. Additionally, the company is exploring the role of infections, such as those caused by Mycoplasma pneumoniae, in triggering asthma attacks and is developing therapeutics that can mitigate these effects. With ongoing NIH funding and a robust pipeline of research, RaeSedo aims to bring a new class of asthma treatments to market, focusing on improving the quality of life for patients suffering from this chronic condition.

United States

RaeSedo, Inc. is a life sciences company that focuses on identifying gaps in asthma therapeutics and uses genomics, human cells, and data to develop innovative solutions. The company has a history of collaborations in the fields of consulting, operational and financial business support, and multidisciplinary assessment and management of severe asthma.

RaeSedo

Company Details